ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας/ IVAXξεγιςεϊ ςμ αηιψδ αιο ξζεξο εξπιεϊ - ςγλεο ξεςγ ρετι17/10/2005 θας ε- IVAX ξεγιςεϊ λι δξεςγ δρετι μδβωϊ δαηιψδ ωμ αςμι ξπιεϊ IVAX απεβς μϊξεψϊ ςρχϊ δψλιωδ ωμ θας ΰϊ IVAX ιεΰψκ μωπι ιξι ςρχιν μτπι ρβιψϊ δςιρχδ. ξεςγ ρβιψϊ δςιρχδ ,λΰξεψ, μΰ πχας ςγιιο. δηαψεϊ ξξωιλεϊ μφτεϊ λι δςιρχδ ϊρβψ αρεσ ωπϊ 2005 ΰε αϊηιμϊ ωπϊ 2006, μΰηψ ριεν ϊδμικ ΰιωεψ Hart-Scott-Rodino, χαμϊ ΰιωεψιν περτιν ξψωειεϊ δβαμιν ςρχιιν εδωμξϊ λμ ϊπΰι ρβιψϊ δςιρχδ δλμεμιν αδρλν δξιζεβ αιο ωπι δφγγιν.
αξρβψϊ ϊπΰι δξιζεβ, μαςμι δξπιεϊ ωμ IVAX δζλεϊ μαηεψ αΰν μχαμ ΰϊ ϊξεψϊ δξιζεβ αξζεξο ΰε αξπιεϊ θας, αλτεσ μηιωεα ιηρι. αϊωχισ δξωεϊσ ωμ θας ε- IVAX ξδ- 23 αρτθξαψ, 2005 φειιο λι δξεςγ δρετι μαηιψδ δεΰ 27 αΰεχθεαψ, 2005, ξεςγ δηετσ μξεςγ χιεν δΰριτεϊ δξιεηγεϊ ωμ αςμι δξπιεϊ ωμ θας ε- IVAX. ϊΰψικ ζδ διδ δϊΰψικ δΰτωψι δξεχγν αιεϊψ ωαε δωμξϊ ςρχϊ δξιζεβ ιλμδ μδϊαφς, αδπηδ λι αςμι δξπιεϊ ωμ ωϊι δηαψεϊ ιΰωψε ΰϊ δςιρχδ.
α-11 αΰεχθεαψ, 2005, χιαμε θας ε- IVAX, λφτει, ξψωεϊ δρηψ δτγψμιϊ αΰψδ"α (FTC) "αχωδ ωπιιδ" (second request) μξιγς περσ απεβς μςιρχδ. μτιλκ, αψεψ ςϊδ λι ϊΰψικ ρβιψϊ δςιρχδ μΰ ιδιδ ξιιγ μΰηψ ΰριτεϊ αςμι δξπιεϊ. αδϊΰν μϊπΰι δρλν δξιζεβ, ιεγιςε δφγγιν ϊΰψικ ρετι ηγω μαηιψδ, μτηεϊ ηξιωδ ιξι ςρχιν μτπι δϊΰψικ δφτει μρβιψϊ ςρχϊ δξιζεβ. ςμ ξπϊ ωαηιψϊν ϊδιδ ιςιμδ, ιδιδ ςμ ξηζιχι ξπιεϊ IVAX μδβιω ΰϊ αηιψϊν μΰ ιΰεηψ ξωπι ιξι ςρχιν μτπι ϊΰψικ ρβιψϊ ςρχϊ δξιζεβ.
αςμι ξπιεϊ ωμ θας ε- IVAXωςγιιο μΰ δφαιςε ξϊαχωιν μςωεϊ ζΰϊ αδχγν εαλμ ξχψδ μτπι δΰριτεϊ δξιεηγεϊ ωπχαςε μ- 27 αΰεχθεαψ, 2005.
μξιγς περσ, αςμι δξπιεϊ ξϊαχωιν μςιιο αϊωχισ ξϊΰψικ 23 αρτθξαψ, 2005, δλεμμ ςεϊχ ξδρλν δξιζεβ. αςμι δξπιεϊ ωμ IVAX ιλεμιν μχαμ ςεϊχιν περτιν ωμ δτψερτχθ, θετρ δαηιψδ εδπηιεϊ περτεϊ ξηαψϊ D. F. King & Co., Inc., δξριιςϊ μ- IVAX, αθμτεο 1-800-549-6697, ΰε μξημχϊ χωψι ξωχιςιν ωμ IVAX αθμτεο 305-575-6000. αςμι ξπιεϊ IVAX ωξπιεϊιδν ξεηζχεϊ ςμ-ιγι αψεχψ ιελμε μχαμ δπηιεϊ ξδαψεχψ. αςμι ξπιεϊ θας ιελμε μχαμ ςεϊχιν περτιν ωμ δτψερτχθ ξηαψϊ MacKenzie Partners, Inc., δξριιςϊ μθας αθμτεο 1-800-322-2885 ΰε μξημχϊ χωψι ξωχιςιν αθας αθμτεο +972-3-926-7554.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20 δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ εαιιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ, διπδ ΰηϊ ξδξεαιμεϊ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο εαξψλζ ΰξψιχδ εαΰιψετδ. χψεα μ- 90% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
About IVAX
IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |